We have focused our studies on elucidating the role and mechanism by which STC2 affects GBM progression, aiming for a comprehensive understanding of the potential role of STC2 as a surrogate marker or therapeutic target for patients with aggressive GBM. Here, STC2 is linked to glioblastoma.